Xu L - Search Results

1

Metabolic and Nonmetabolic Functions of PSAT1 Coordinate Signaling Cascades to Confer EGFR Inhibitor Resistance and Drive Progression in Lung Adenocarcinoma.

Luo MY, Zhou Y, Gu WM, Wang C, Shen NX, Dong JK, Lei HM, Tang YB, Liang Q, Zou JH, Xu L, Ma P, Zhuang G, Bi L, Xu L, Zhu L, Chen HZ, Shen Y. Luo MY, et al. Among authors: xu l. Cancer Res. 2022 Oct 4;82(19):3516-3531. doi: 10.1158/0008-5472.CAN-21-4074. Cancer Res. 2022. PMID: 36193649

2

Blocking M2 muscarinic receptor signaling inhibits tumor growth and reverses epithelial-mesenchymal transition (EMT) in non-small cell lung cancer (NSCLC).

Zhao Q, Gu X, Zhang C, Lu Q, Chen H, Xu L. Zhao Q, et al. Among authors: xu l. Cancer Biol Ther. 2015;16(4):634-43. doi: 10.1080/15384047.2015.1029835. Epub 2015 Mar 16. Cancer Biol Ther. 2015. PMID: 25778781 Free PMC article.

3

Inactivation of M2 AChR/NF-κB signaling axis reverses epithelial-mesenchymal transition (EMT) and suppresses migration and invasion in non-small cell lung cancer (NSCLC).

Zhao Q, Yue J, Zhang C, Gu X, Chen H, Xu L. Zhao Q, et al. Among authors: xu l. Oncotarget. 2015 Oct 6;6(30):29335-46. doi: 10.18632/oncotarget.5004. Oncotarget. 2015. PMID: 26336823 Free PMC article.

4

Role of α7-nicotinic acetylcholine receptor in nicotine-induced invasion and epithelial-to-mesenchymal transition in human non-small cell lung cancer cells.

Zhang C, Ding XP, Zhao QN, Yang XJ, An SM, Wang H, Xu L, Zhu L, Chen HZ. Zhang C, et al. Among authors: xu l. Oncotarget. 2016 Sep 13;7(37):59199-59208. doi: 10.18632/oncotarget.10498. Oncotarget. 2016. PMID: 27409670 Free PMC article.

5

Acquisition of EGFR TKI resistance and EMT phenotype is linked with activation of IGF1R/NF-κB pathway in EGFR-mutant NSCLC.

Li L, Gu X, Yue J, Zhao Q, Lv D, Chen H, Xu L. Li L, et al. Among authors: xu l. Oncotarget. 2017 Sep 21;8(54):92240-92253. doi: 10.18632/oncotarget.21170. eCollection 2017 Nov 3. Oncotarget. 2017. PMID: 29190911 Free PMC article.

6

Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3.

Yue J, Lv D, Wang C, Li L, Zhao Q, Chen H, Xu L. Yue J, et al. Among authors: xu l. Oncogene. 2018 Aug;37(31):4300-4312. doi: 10.1038/s41388-018-0276-2. Epub 2018 May 2. Oncogene. 2018. PMID: 29717264 Free PMC article.

7

CuS Nanoparticles as a Photodynamic Nanoswitch for Abrogating Bypass Signaling To Overcome Gefitinib Resistance.

Gu X, Qiu Y, Lin M, Cui K, Chen G, Chen Y, Fan C, Zhang Y, Xu L, Chen H, Wan JB, Lu W, Xiao Z. Gu X, et al. Among authors: xu l. Nano Lett. 2019 May 8;19(5):3344-3352. doi: 10.1021/acs.nanolett.9b01065. Epub 2019 Apr 24. Nano Lett. 2019. PMID: 30974946

8

Acquired Resistance to EGFR TKIs Mediated by TGFβ1/Integrin β3 Signaling in EGFR-Mutant Lung Cancer.

Wang C, Wang T, Lv D, Li L, Yue J, Chen HZ, Xu L. Wang C, et al. Among authors: xu l. Mol Cancer Ther. 2019 Dec;18(12):2357-2367. doi: 10.1158/1535-7163.MCT-19-0181. Epub 2019 Sep 9. Mol Cancer Ther. 2019. PMID: 31501278

9

Repositioning Aspirin to Treat Lung and Breast Cancers and Overcome Acquired Resistance to Targeted Therapy.

Li L, Hu M, Wang T, Chen H, Xu L. Li L, et al. Among authors: xu l. Front Oncol. 2020 Jan 14;9:1503. doi: 10.3389/fonc.2019.01503. eCollection 2019. Front Oncol. 2020. PMID: 31993373 Free PMC article.

10

Metformin Overcomes Acquired Resistance to EGFR TKIs in EGFR-Mutant Lung Cancer via AMPK/ERK/NF-κB Signaling Pathway.

Li L, Wang T, Hu M, Zhang Y, Chen H, Xu L. Li L, et al. Among authors: xu l. Front Oncol. 2020 Sep 10;10:1605. doi: 10.3389/fonc.2020.01605. eCollection 2020. Front Oncol. 2020. PMID: 33014814 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

41,017 results

Search Page

Filters